{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=All+oral+administration+group",
    "query": {
      "intervention": "All oral administration group"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 299,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=All+oral+administration+group&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T01:03:52.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04879368",
      "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastro-Oesophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine/Tipracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Australasian Gastro-Intestinal Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2021-05-05",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04879368"
    },
    {
      "nct_id": "NCT00342849",
      "title": "Treatment of Lead-Exposed Children Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lead Exposure"
      ],
      "interventions": [
        {
          "name": "Succimer",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Environmental Health Sciences (NIEHS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "33 Months",
        "sex": "ALL",
        "summary": "12 Months to 33 Months"
      },
      "enrollment_count": 780,
      "start_date": "1994-07-15",
      "completion_date": "2015-06-10",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Newark, New Jersey • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00342849"
    },
    {
      "nct_id": "NCT04089852",
      "title": "Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Contraceptive Devices",
        "Long-Acting Reversible Contraception",
        "Analgesia",
        "Adolescent Health",
        "Gynecology"
      ],
      "interventions": [
        {
          "name": "Nitrous oxide gas for inhalation",
          "type": "DRUG"
        },
        {
          "name": "Oxygen Gas for Inhalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "24 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 24 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-01",
      "completion_date": "2021-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-16",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04089852"
    },
    {
      "nct_id": "NCT02563327",
      "title": "Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2516,
      "start_date": "2016-01-25",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02563327"
    },
    {
      "nct_id": "NCT02734862",
      "title": "CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Candidemia",
        "Mycoses",
        "Fungal Infection",
        "Fungemia",
        "Invasive Candidiasis"
      ],
      "interventions": [
        {
          "name": "CD101",
          "type": "DRUG"
        },
        {
          "name": "Caspofungin",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "intravenous placebo",
          "type": "DRUG"
        },
        {
          "name": "oral placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2016-07-26",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Davis, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02734862"
    },
    {
      "nct_id": "NCT07360301",
      "title": "Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Well-Being, Psychological",
        "Psychedelic Experiences"
      ],
      "interventions": [
        {
          "name": "Psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "OTHER"
        },
        {
          "name": "Clonidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-09",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07360301"
    },
    {
      "nct_id": "NCT04484337",
      "title": "Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir sodium (Oral Lead In)",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 400 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 200 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Topical Non-steroidal anti-inflammatory drug (NSAID)",
          "type": "DRUG"
        },
        {
          "name": "Topical steroid",
          "type": "DRUG"
        },
        {
          "name": "Topical NSAID placebo",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        },
        {
          "name": "Topical steroid placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 138,
      "start_date": "2020-07-31",
      "completion_date": "2023-05-05",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484337"
    },
    {
      "nct_id": "NCT04877522",
      "title": "Asciminib Roll-over Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia",
        "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
      ],
      "interventions": [
        {
          "name": "Asciminib single agent",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "Bosutinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Asciminib single agent pediatric formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "7 Years to 100 Years"
      },
      "enrollment_count": 347,
      "start_date": "2022-08-30",
      "completion_date": "2030-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 6,
      "location_summary": "Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04877522"
    },
    {
      "nct_id": "NCT01227512",
      "title": "Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyponatremia",
        "Dilutional Hyponatremia",
        "Inappropriate ADH Syndrome"
      ],
      "interventions": [
        {
          "name": "tolvaptan",
          "type": "DRUG"
        },
        {
          "name": "Fluid Restriction",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2010-10",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-10-30",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Azusa, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Banning",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227512"
    },
    {
      "nct_id": "NCT04933799",
      "title": "IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "PF-06650833",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Giovanni Franchin, M.D, Ph.D",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2021-01-06",
      "completion_date": "2022-05-06",
      "has_results": false,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-09-04T01:03:52.281Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04933799"
    }
  ]
}